Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules in Patients with Chronic Osteoarthritis Pain

References

• . Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv. 2006;3(4):489–497
   PubMedGoogle Scholar
• . Woolf CJ, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Invest Drugs. 2004;5(1):61–66
   PubMedGoogle Scholar
• . Katz NP, Adams EH, Chilcoat H. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648–660
   PubMed Web of Science ®Google Scholar
• . Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507–513
   PubMed Web of Science ®Google Scholar
• . Goodwin JL, Kraemer JJ, Bajwa ZH. The use of opioids in the treatment of osteoarthritis: when, why, and how? Curr Pain Headache Rep. 2005;9(6):390–398
   PubMedGoogle Scholar
• . Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434, 2009). Rockville, MD. http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.pdf. Accessed June 9, 2010
   Google Scholar
• . Butler SF, Budman SH, Licari A,. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17(12):1142–1154
   PubMed Web of Science ®Google Scholar
• . EMBEDA [package insert]. Bristol, TN: King Pharmaceuticals®, Inc.; June 2009
   Google Scholar
• . Ross EL, Hahn K. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain. Int J Clin Pract. 2008;62(3):471–479
   PubMed Web of Science ®Google Scholar
• . KADIAN [package insert]. Elizabeth, NJ: Actavis Elizabeth, LLC; February 2009
   Google Scholar
• . Johnson F, Jones JB, Stauffer J. Relative bioavailability of plasma naltrexone from crushed ALO-01 (an investigational, abuse-deterrent, extended-release, morphine sulfate formulation with sequestered naltrexone) to a naltrexone oral solution [abstract]. J Pain. 2008;9(4 suppl 2):35
   Google Scholar
• . Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29(12):777–790
   PubMed Web of Science ®Google Scholar
• . Katz NP, Sun S, Johnson FK, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain. 2010;11(4):303–311
   PubMed Web of Science ®Google Scholar
• . Altman RA, Asch E, Bloch D,. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039–1049
   PubMed Web of Science ®Google Scholar
• . Altman RA, Alarcón GS, Appelrouth D,. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34(5):505–514
   PubMed Web of Science ®Google Scholar
• . Lemmens HJ, Wada DR, Munera C, Eltahtawy A, Stanski DR. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials. 2006;27(2):165–173
   PubMed Web of Science ®Google Scholar
• . McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrollment with randomized withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain. 2008;135(3):217–220
   PubMed Web of Science ®Google Scholar
• . Katz N, Rauck R, Ahdieh H,. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23(1):117–128
   PubMed Web of Science ®Google Scholar
• . Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138
   PubMedGoogle Scholar
• . Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–1840
   PubMed Web of Science ®Google Scholar
• . Spritzer KL, Hays RD. MOS Sleep Scale: A Manual for Use and Scoring, Version 1.0. Los Angeles, CA: RAND; November 2003
   Google Scholar
• . Hays RD, Stewart AL. Sleep measures. In: Stewart A, Ware J, eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:235–259
   Google Scholar
• . Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571
   PubMed Web of Science ®Google Scholar
• . Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253–259
   PubMed Web of Science ®Google Scholar
• . Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293–308
   PubMed Web of Science ®Google Scholar
• . Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. J Pain Symptom Manage. 2006;31(4):369–377
   PubMed Web of Science ®Google Scholar
• . Hale ME, Ahdieh H, Ma T, Rauck R; Oxymorphone ER Study Group 1. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175–184
   PubMed Web of Science ®Google Scholar
• . Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–158
   PubMed Web of Science ®Google Scholar
• . Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology. 2005;65(12 suppl 4):S32–S49
   Google Scholar
• . Nicholson B, Ross E, Sasaki J, Weil A. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin. 2006;22(8):1503–1514
   PubMed Web of Science ®Google Scholar
• . Nicholson B, Ross E, Weil A, Sasaki J, Sacks G. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules. Curr Med Res Opin. 2006;22(3):539–550
   PubMed Web of Science ®Google Scholar
• . Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287(5):622–627
   PubMed Web of Science ®Google Scholar
• . Webster L, Jones JB, Johnson F, Sekora D, Stauffer J. Relative drug-liking/euphoria effects of intravenous morphine alone and in combination with naltrexone in recreational opioid users [abstract no. 2993]. Abstract presented at: International Association for the Study of Pain 12th World Congress on Pain; August 17–22, 2008; Glasgow, Scotland
   Google Scholar